FBLG FibroBiologics Inc.: Company Short-Term Debts

Public company logo of FibroBiologics Inc. (FBLG)

The GURU.Markets terminal provides a chart of the short-term liability structure for FibroBiologics, Inc. (FBLG), where the 0.00 mark serves as the current indicator. This trend is based on a protected patent portfolio that guarantees a stable cash flow. Leading regenerative scientists operating without bureaucracy drive growth, while the implementation of laboratory robots and predictive data analysis software enhances efficiency.

FBLG (FibroBiologics, Inc.) Short-Term Debt history from 02/21/2024 to 10/30/2026

FibroBiologics Inc. - analytical breakdowns and key metrics (FBLG)

- current quotes and average value forecast:
Price Chart FibroBiologics Corp|FBLG - Consensus Target
- company stock capitalization data:
Market Capitalization FibroBiologics, Inc.|FBLG - Real Price to Acquire Entire Company
- business book valuation details:
Book Value per Share FibroBiologics|FBLG - Total Stockholders' Equity|Market Value to Book Value Ratio fibrobiologics.com|FBLG - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity FibroBiologics, Inc.|FBLG - Long-Term Debt to Equity|Short-Term Debt to Equity FibroBiologics Corp|FBLG - Company Total Debt Obligations|Debts to Book Capitalization FibroBiologics, Inc.|FBLG - Long-Term Liabilities|Company Short-Term Debts FibroBiologics|Quick Ratio fibrobiologics.com
- net income and valuation multiples indicators:
FBLG - Company Net Income
Fundamental company analysis:fibrobiologics.com (FBLG)
Mass-produced product of FibroBiologics Corp

This indicator measures the density of the current credit load, allowing investors to assess the actual pace of debt repayment and eliminate the risk of hidden asset sales used to balance accounts. By analyzing short-term financial debts with maturities of up to one year, one can confirm the financial stability of FibroBiologics, Inc. (FBLG) during the implementation of costly developments in regenerative medicine and multiple sclerosis therapy.

Key competitors

MESO - Company Short-Term Debt|Lineage Cell Therapeutics Inc (LCTX) - Company Current Liabilities|SRZN: Company Short-Term Debts|Company Current Liabilities Cryo-Cell International, Inc.|LGVN (Longeveron Inc.) - Company Short-Term Debts|Short-Term Debt BioRestorative BRTX|Company Short-Term Debt Creative Medical Technology (CELZ)